The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion.
Sales of its COVID-19 vaccine dropped to $28 million in the first quarter, versus $1.14 billion over the same period last year, as the company lost ground to rival mRNA shots.Excluding sales of its COVID-19 products, sales rose 22% to $3.1 billion in emerging markets on a constant currency basis. Sales in China were hurt last year by lower drug prices, while the country's tough zero-COVID policy, which was abandoned in December, has kept some patients from being diagnosed and seeking care.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: